Nuvalent, Inc. (NUVL)

NASDAQ: NUVL · IEX Real-Time Price · USD
31.01
-0.55 (-1.74%)
At close: Dec 9, 2022 4:00 PM
30.88
-0.13 (-0.42%)
After-hours: Dec 9, 2022 5:15 PM EST
-1.74%
Market Cap 1.78B
Revenue (ttm) n/a
Net Income (ttm) -73.02M
Shares Out 48.41M
EPS (ttm) -1.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 159,966
Open 31.51
Previous Close 31.56
Day's Range 30.73 - 32.33
52-Week Range 7.09 - 40.43
Beta n/a
Analysts Buy
Price Target 44.54 (+43.6%)
Earnings Date Nov 9, 2022

About NUVL

Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent ... [Read more]

Industry Biotechnology
IPO Date Jul 29, 2021
Employees 57
Stock Exchange NASDAQ
Ticker Symbol NUVL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for NUVL stock is "Buy." The 12-month stock price forecast is 44.54, which is an increase of 43.63% from the latest price.

Price Target
$44.54
(43.63% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Here's Why Momentum in Nuvalent, Inc. (NUVL) Should Keep going

Nuvalent, Inc. (NUVL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through o...

1 week ago - Zacks Investment Research

What Makes Nuvalent, Inc. (NUVL) a Strong Momentum Stock: Buy Now?

Does Nuvalent, Inc. (NUVL) have what it takes to be a top stock pick for momentum investors? Let's find out.

3 weeks ago - Zacks Investment Research

Nuvalent Reviews Corporate and Pipeline Achievements and Reports Third Quarter 2022 Financial Results

Preliminary Phase 1 clinical data from ARROS-1 Study presented at the 2022 EORTC-NCI-AACR Symposium supports best-in-class potential of NVL-520 for patients with ROS1-positive NSCLC Enrollment progressi...

4 weeks ago - PRNewsWire

Nuvalent Announces Closing of Upsized Public Offering of Common Stock

CAMBRIDGE, Mass. , Nov. 3, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ta...

1 month ago - PRNewsWire

Nuvalent Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass. , Oct. 31, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase t...

1 month ago - PRNewsWire

Nuvalent Announces Public Offering of Common Stock

CAMBRIDGE, Mass. , Oct. 31, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase t...

1 month ago - PRNewsWire

Recent IPO Stock Nuvalent Is Flirting With A Record High On A Tricky Cancer Win

Recent IPO stock Nuvalent Therapeutics surged within striking distance of a record high Friday on promising test results in lung cancer. The post Recent IPO Stock Nuvalent Is Flirting With A Record High...

1 month ago - Investors Business Daily

Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520...

Favorable preliminary safety profile of NVL-520 suggests potential for a highly ROS1-selective, TRK sparing design, with no dose-limiting toxicities, treatment-related serious adverse events, treatment-...

1 month ago - PRNewsWire

Nuvalent Announces New Preclinical Data for Selective Kinase Inhibitors NVL-330 and NVL-655

Preclinical data demonstrated that NVL-330 inhibits HER2 exon 20 insertion mutations, is selective for HER2 versus wild-type EGFR, and is brain-penetrant NVL-655 preclinical data further support its bes...

1 month ago - PRNewsWire

Nuvalent to Host Conference Call to Discuss Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 and Addit...

CAMBRIDGE, Mass. , Oct. 17, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase t...

1 month ago - PRNewsWire

Nuvalent Appoints Michael L. Meyers, MD, PhD, to Board of Directors

CAMBRIDGE, Mass. , Oct. 6, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ta...

2 months ago - PRNewsWire

Nuvalent to Present Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 at 34th EORTC-NCI-AACR Symposium ...

Preliminary Dose Escalation Data on ROS1-selective Inhibitor NVL-520 to be Presented in the "New Drugs on the Horizon" Oral Plenary Session New Preclinical Data to be Presented on Parallel-lead, Clinica...

3 months ago - PRNewsWire

Nuvalent to Participate in the Wells Fargo 2022 Healthcare Conference

CAMBRIDGE, Mass. , Sept. 1, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase t...

3 months ago - PRNewsWire

Nuvalent Highlights Execution Across Pipeline of Novel Kinase Inhibitors and Reports Second Quarter 2022 Financial Re...

Preliminary dose escalation data expected in second half of 2022 from the ARROS-1 study of NVL-520 for advanced ROS1 positive NSCLC and other solid tumors Rapid advancement of pipeline with clinical tri...

3 months ago - PRNewsWire

Nuvalent Presents New Preclinical Data Supporting Potential Best-in-Class Profile for ALK-Selective Inhibitor NVL-655...

Trial in progress poster also to be presented for Phase 1/2 ARROS-1 study of ROS1-selective inhibitor NVL-520 CAMBRIDGE, Mass. , Aug. 5, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-st...

4 months ago - PRNewsWire

Nuvalent to Present at the Canaccord Genuity 42nd Annual Growth Conference

CAMBRIDGE, Mass. , Aug. 3, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ta...

4 months ago - PRNewsWire

Nuvalent Announces Leadership Promotions

Darlene Noci, A.L.M. promoted to Chief Development Officer Benjamin Lane, Ph.D.

4 months ago - PRNewsWire

Nuvalent to Present New NVL-655 Preclinical Data and ARROS-1 Trial in Progress Poster for NVL-520 at IASLC 2022 World...

Preclinical activity of ALK-selective inhibitor NVL-655 in a lorlatinib-resistant model of NSCLC with a compound resistance mutation continues to support potential for best-in-class profile CAMBRIDGE, M...

4 months ago - PRNewsWire

Nuvalent Announces Clinical Progress on Parallel Lead Programs NVL-520 and NVL-655 for NSCLC and Solid Tumor Cancers

Preliminary dose-escalation data anticipated in second half of 2022 for ongoing ARROS-1 Phase 1/2 clinical trial of NVL-520 for patients with advanced ROS1-positive NSCLC and other solid tumors First pa...

5 months ago - PRNewsWire

Nuvalent to Present at the 2022 Jefferies Healthcare Conference

CAMBRIDGE, Mass. , June 2, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ta...

6 months ago - PRNewsWire

Nuvalent Highlights Pipeline and Business Progress and Reports First Quarter 2022 Financial Results

Two clinical-stage programs ongoing for potential best-in-class ROS1 and ALK-selective inhibitors On-track for selection of two additional development candidates in 2022 Ended the first quarter of 2022 ...

6 months ago - PRNewsWire

Nuvalent Presents New Data Demonstrating Expanded Preclinical Activity with ROS1-Selective Inhibitor NVL-520 and ALK-...

NVL-520 showed strong preclinical activity against diverse ROS1 fusion partners and kinase-domain resistance mutations, as well as in a ROS1-driven model of glioblastoma NVL-655 demonstrated differentia...

8 months ago - PRNewsWire

Nuvalent to Participate in the 2022 Canaccord Genuity Horizons in Oncology Virtual Conference

CAMBRIDGE, Mass. , April 7, 2022 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ: NUVL), a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase t...

8 months ago - PRNewsWire

Nuvalent Appoints Anna Protopapas as Chair of Board of Directors

Veteran Biotech Executive with Broad Oncology Perspective to Lead Nuvalent Board as Company Advances its Pipeline of Precisely Targeted Therapies CAMBRIDGE, Mass. , March 31, 2022 /PRNewswire/ -- Nuvale...

8 months ago - PRNewsWire

Nuvalent Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results

NVL-655 IND cleared by FDA, supporting planned initiation of ALKOVE-1 Phase 1/2 clinical trial in patients with ALK-positive NSCLC and other solid tumors in second quarter of 2022 Enrollment ongoing in ...

8 months ago - PRNewsWire